Retatrutide Phase 2a MASLD liver-fat substudy
At week 24, mean liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% versus +0.3% placebo; 79% and 86% at 8/12 mg reached <5% liver fat.
What this study tells us
Participants were assigned to comparison groups by chance, usually with placebo and/or blinding to reduce bias. This is a strong design for testing cause and effect, but the population, duration and endpoints still limit what can be concluded.
Adults with obesity/overweight and MASLD with >=10% liver fat
n=98
At week 24, mean liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% versus +0.3% placebo; 79% and 86% at 8/12 mg reached <5% liver fat.
Substudy sample is much smaller than the main obesity trial; liver-fat improvement is not yet an approved MASLD indication.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
At week 24, mean liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% versus +0.3% placebo; 79% and 86% at 8/12 mg reached <5% liver fat.